title: Concerns about idarucizumab for dabigatran reversal.
authors.affiliation: aKrankenanstalt Rudolfstiftung, Wien, Austria bGesundheitszentrum Oberammergau, Oberammergau cSana Kliniken Lübeck, Lübeck, Germany.
authors.forename: Claudia
authors.initials: C
authors.lastname: Stöllberger
authors.forename: Peter
authors.initials: P
authors.lastname: Pommer
authors.forename: Birke
authors.initials: B
authors.lastname: Schneider
authors.forename: Josef
authors.initials: J
authors.lastname: Finsterer
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D000069604:Dabigatran / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006801:Humans; D012107:Research Design; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; C000594745:idarucizumab; D000069604:Dabigatran